NCT01526044

Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients

Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients; a Randomized Controlled Trial (RESCUEII)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 178 (actual)
• Sponsor: Onze Lieve Vrouwe Gasthuis · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the accuracy and reliability of the continuous glucose monitoring system the FreeStyle Navigator® (Abbott, Diabetes Care) in critically ill patients by comparing subcutaneous measuring with the current standard of arterial measuring by a point of care glucometer.

Detailed description

Most patients admitted to the ICU are treated with intensive insulin therapy, according to a locally developed glucose treatment protocol. The use of a continuous glucose monitoring in critically ill patients could have the following advantages: * Better insight in the alterations of the blood glucose levels * Early detection of hypoglycemia's or hyperglycaemia's, and subsequently more stable glycemic levels. * Fewer blood samples * Decreased workload for the nursing staff In this study, patients will be randomized in: 1. The Freestyle group or 2. The AccuChek Group. Patients in both groups will receive a Freestyle Navigator device, which will stay on the patient up to 5 days, or until discharge from the ICU. The medical treatment of both study groups will be equal, except for the frequency of the glucose level measurements and the resulting adjustments according to the treatment protocol. In the Freestyle group extra glucose level measurements will be made in response to alarms from the device. In both groups, every 4 hours blood glucose values will be obtained using a blood gas analyzer (BGA). When a control measurement by BGA results in a glucose level of \<2.2 or \>25 mmol/l, the value will be transmitted to the Patient Data Management System (PDMS) and gives an alarm. Otherwise, the value will be blinded in the PDMS. Freestyle Navigator data will be downloaded from the device. Blood glucose values obtained in the course of usual care will be compared with time-matched Freestyle Navigator values to assess device accuracy.

Conditions

• Hyperglycaemia
• Hypoglycaemia

Interventions

Type	Name	Description
DEVICE	Freestyle Navigator	Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid

Timeline

• Start date: 2010-12-01
• Primary completion: 2012-04-01
• Completion: 2012-06-01
• First posted: 2012-02-03
• Last updated: 2012-06-27

Locations

1 site across 1 country: Netherlands